Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.
about
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory DiseasesRole of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazineLong-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Management of the elderly patients with inflammatory bowel disease: practical considerations.Drug Management in the Elderly IBD Patient.Treatment Nonadherence in Inflammatory Bowel Disease: Identification, Scope, and Management Strategies.Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions.Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study.Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly.Electrical, enzymatic graphene biosensing of 5-aminosalicylic acid.A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
P2860
Q26778585-F55119BE-8F3E-41CD-8CCA-2431FEB96A9EQ33628518-5C61739A-963F-4B1E-A669-304A8BD61247Q34273329-033FA9A3-1727-470F-9E41-FD60EA442009Q36144377-38F32A25-A414-4BA9-96A5-DCB8DD13FE29Q38122069-A15B6DF5-B15C-4C66-97A5-CBCED006FBB4Q38330651-BF81E5E3-A339-4DCE-9867-AE06114B90FBQ38583997-F9BF5315-43B0-4DFD-86DF-C963C3FB3962Q38768891-1347EBF8-8BA2-4113-A6D1-DD058F07437FQ40052034-F6CA0DC8-DC37-4283-AF6A-AAC40A1BDC5FQ41169995-A2ACFACE-86AF-40A1-9419-B66CDCEE8FA6Q44344227-8FA748AC-511E-4D5D-9F72-B83CC63174C1Q45922212-242EA88D-6FD2-4BC8-B2CF-797888CCE4E4Q48064807-6B7EC9F5-9C9F-4588-8CEB-2F6732B595C2Q48346132-3C255692-CD03-4F00-8BE5-34FE6114CE1C
P2860
Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Twelve-month persistency with ...... armacy prescriptions database.
@en
Twelve-month persistency with ...... armacy prescriptions database.
@nl
type
label
Twelve-month persistency with ...... armacy prescriptions database.
@en
Twelve-month persistency with ...... armacy prescriptions database.
@nl
prefLabel
Twelve-month persistency with ...... armacy prescriptions database.
@en
Twelve-month persistency with ...... armacy prescriptions database.
@nl
P2093
P2860
P1476
Twelve-month persistency with ...... armacy prescriptions database.
@en
P2093
Dory Solomon
Matthew Jenkins
Michael Sumner
Sunanda V Kane
P2860
P2888
P304
P356
10.1007/S10620-011-1877-6
P577
2011-08-31T00:00:00Z